BASF And Poietis Sign A Research And Development Agreement On 3D Bioprinting Technology For Advanced Skin Care Applications


Sign up online today & collaborate

or click here to find out more

BASF And Poietis Sign A Research And Development  Agreement On 3D Bioprinting Technology For Advanced Skin Care  Applications


Date: 20/07/2015

Combined expertise to enhance bioprinted 3D tissue models to support the development and testing of cosmetic bioactives for skin care applications

Ludwigshafen, Germany / Pessac, France – July 10, 2015 – BASF and Poietis, the first company in the world for 3D laser-assisted bioprinting, have signed an agreement on research and development in cosmetics. Based on the combined expertise of both companies in tissue engineering and bioprinting, the agreement aims to apply the bioprinting technology of Poietis to improve BASF’s skin equivalent model Mimeskin™. The terms and conditions of this agreement were not disclosed.

The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows for a precise positioning of the skin cells in three-dimensional structures. Through this, cells are cultivated within BASF’s skin model Mimeskin™, which is the closest equivalent to the original physiological tissue of human skin. Dr. Fabien Guillemot, Founder and President of Poietis, remarks: “We are extremely pleased about this collaboration. Having long-term expertise in solutions for the dermocosmetics market, BASF understands the benefits of 3D laser-assisted bioprinting compared to conventional cell culture technologies and other bioprinting methods. The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy.”

For more click here

Source: World press Online

© Catalyst Innovation Portal 2019